Cannabis has been receiving some serious media attention in 2018, and a rise in medical cannabis research is following.
Harmful algal blooms (HABs) have been reported in every US coastal state and their occurrence is likely on the rise, according to the US National Oceanic and Atmospheric Administration (NOAA).
Pharma giant Merck is seeking a patent for a blockchain-based system to track objects as they navigate through the supply chain.
Cases of tick-borne diseases are on the rise globally, with Lyme disease patients increasing by over three-fold in the US alone in the past couple years.
US President Trump’s proposed tariffs on China could ignite a US-China trade war and destabilise an already shaky pharma industry.
The early and accurate diagnosis of autism spectrum disorder (ASD) in children is crucial.
Takeda’s possible $65 billion takeover of Shire could be the largest deal value in pharma this year and combined Takeda Shire company could be catapulted to the ninth position in terms of 2017 sales.
The theme of World Malaria Day 2018 is “Ready to Beat Malaria”, highlighting the collective global goal to end the disease.
In 2016, more than 110 people died every day due to opioid overdose in the US.
Many research groups and private companies are attempting to develop a test that can accurately and effectively determine whether or not a person has cancer.
The US Senate passed the country’s first major tax reform in over 30 years last month, and the ramifications on the pharmaceutical industry could be vast.
Wearable devices can be used to detect the early signs of diabetes using an artificial intelligence (AI) network called DeepHeart and developed by Cardiogram, a study has found.
Earlier this week US president Donald Trump described the UK’s National Health Service (NHS) as “going broke and not working.” Although many were quick to criticise him this description may hit too close to home for some in the NHS.
With increasingly intelligent artificial intelligence (AI), even high level surgeons might soon be finding themselves replaced by robots as AI exceeds human abilities.
Flu season now is in full swing, with four strains in circulation this year.
Long suffering patients in US hospital have for years had to pay for expensive drugs because cheaper alternatives are in short supply.
In the pharmaceutical industry one well performing drug can make or break a company’s year.
People that think vaccines are dangerous — so-called anti-vaxxers — are a small but dangerous group.
In all developed countries around the world women are more likely than men to be diagnosed with Alzheimer’s.
Despite a rise in awareness of the dangers of sun damage to the skin the number of people diagnosed with melanoma is expected to rise in both men and women between now and 2026.
Artificial intelligence (AI) is coming to almost every aspect of day-to-day life.
Migraines are relatively common, affecting approximately 11 percent of the world’s adult population.
The number of drugs picking up a designation from regulators — first treatments or speciality drugs — across the European Union, the US, and Japan have risen by 117 percent in 10 years.
Novartis, the Swiss multinational pharma giant, carried out the most clinical trials in Japan since 2012, with almost 150.
Healthcare systems around the world are under unprecedented financial pressure.
Humira has set a record for the highest gross-selling drug in the world and contributed 63 percent to AbbVie’s revenue in 2016 alone and expectations are high the blockbuster drug will continue to perform.
The ability to edit the human genome has been eagerly anticipated for many years.
While uncertainty has been a theme for most sectors in the UK over recent months, the medical technology (medtech) industry has suffered more than most.
Heart surgery, prenatal care, organ transplants, and blood transfusions.
There is bad news for global pharmaceutical and medical devices companies; China has developed a set-in-stone timetable to conduct government-driven price management and reimbursement controls.